Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering Effect
Table 4
IOP reduction at first and second visits.
Total responders
Nonresponders
Initial responders
Long-term responders
Robust long-termresponders
Super responders
First visit (mmHg)
−2.84 ± 0.30
3.80 ± 0.50
−2.79 ± 0.37
−3.07 ± 0.27
−5.16 ± 0.32
−11.41 ± 0.98
First visit (%)
−14.18 ± 22.16
22.40 ± 17.13
−14.71 ± 12.37
−16.85 ± 10.97
−29.53 ± 9.01
−45.56 ± 15.59
First visit p value
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
Second visit (mmHg)
−3.01 ± 0.44
0.63 ± 1.08
0.05 ± 0.87
−3.53 ± 0.39
−5.66 ± 0.33
−12.30 ± 1.10
Second visit (%)
−14.94 ± 28.04
4.13 ± 27.99
1.02 ± 32.18
−18.71 ± 11.76
−34.27 ± 9.78
−48.13 ± 16.89
Second visit value
<0.0001
0.5637
0.9583
<0.0001
<0.0001
<0.0001
mmHg = millimeters of mercury. Mean and SD Rhopressa duration (in days) at instance 1: 55.66 ± 51.89 days. Mean and SD Rhopressa duration (in days) at instance 2: 133.24 ± 77.63 days.
